AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (1999)
25 slides from AstraZeneca's investor presentation, 1999
Slide 1: AstraZeneca Oncology: Living Longer and Better
AstraZeneca Oncology Brent M Vose Vice President & Head of Oncology TA Living Longer and Better
Slide 2: AstraZeneca innovation
AstraZeneca innovation h 1st registration in prevention - Nolvadex® h 1st to demonstrate advantage of one hormonal agent over another - Arimidex® h 1st to provide quality of life option in prostate cancer - Casodex® A success story that we will build on Overall market - key growth drivers h Ageing p
Slide 3: AstraZeneca cancer portfolio and disease management
AstraZeneca cancer portfolio Portfolio Hormones Cytotoxics New approaches Nolvadex® Tomudex® Iressa™ Zoladex® ZD9331 ZD6126 Casodex® ZD0473 ZD6474 Arimidex® VTK Faslodex™ FAR ZD1059 PAR AstraZeneca has products in each of these segments AstraZeneca disease management Diseases Prostate Cancer Breast
Slide 4: Breast cancer treatment continuum
Breast cancer treatment continuum h Nolvadex benefits h Women at increased risk 49% h Contralateral breast cancer 47% h Ductal carcinoma in situ 43% h Node negative breast cancer 47% h Node positive breast cancer 47% Arimidex - aromatase inhibitors Market share vs competitors within the aromatase in
Slide 5: Arimidex vs Nolvadex
Arimidex® vs Nolvadex® In post-menopausal first line breast cancer treatment h To prove Arimidex® to be as effective as Nolvadex® with a better tolerability and QoL profile h The trials of primary therapy of advanced breast cancer are “stepping stones” to the adjuvant indication Arimidex® vs Nolvade
Slide 6: Arimidex changes the paradigm
Arimidex® changes the paradigm h First line advanced breast cancer trials show that Arimidex® may have superior efficacy to Nolvadex® h Arimidex® gives survival advantages over Megace in second line breast cancer h Confirmation of superiority in the adjuvant setting (ATAC trial) will leave Arimidex®
Slide 7: Development times; Faslodex new therapy for breast cancer
Development times Arimidex® 9 Yrs Time until first launch in ABC Time until launch of first trials in Time until launch of EBC first results in EBC Time until US launch in EBC Nolvadex® 16 Yrs 0 5 10 15 Years First trials in advanced breast cancer T=0 Faslodex™ - new therapy for breast cancer h Uniq
Slide 8: Faslodex - improvement over current therapies
Faslodex™ - improvement over current therapies h Superior median duration of response in 2nd line h Effective in Nolvadex® resistant tumours h 2nd line studies designed to show superior efficacy to Arimidex® - submission 2Q 2000 h 1st line studies designed to show superior efficacy and tolerability
Slide 9: Prostate cancer market
Prostate cancer market h Most common diagnosed cancer in men h Second leading cause of cancer fatalities among men h Trend towards earlier diagnosis and treatment h 80% of patients respond to hormone therapy h Treatment goals – improve survival – early disease – improve QoL – all stages of disease A
Slide 10: Casodex monotherapy
Casodex® monotherapy h Current treatment of prostate cancer is medical or surgical castration which results in lost libido, lost energy, bone loss Cumulative incidence of osteoporotic fractures in prostate cancer patients (Daniell, 1977) Cumulative 50 Orchidectomy incidence (%) No orchidectomy 40 30
Slide 11: Casodex monotherapy survival
Casodex® monotherapy h No difference in survival for patients with locally advanced prostate cancer when compared with castration h More likely to retain physical capacity, sexual interest and function and maintain bone mineral density h Avoid the side effects of castration h Already approved in UK,
Slide 12: Casodex in early prostate cancer
Difference between Casodex® 150 mg and castration in bone mineral density % difference Femoral neck Lumbar spine Based on the mean +20.0% +12.8% Positive % differences indicate an advantage for Casodex® No bone loss on Casodex® Casodex® in early prostate cancer h Recruitment of 8113 patients complet
Slide 13: Cytotoxics
Zoladex in prostate cancer Cytotoxics h The mainstay of cancer treatment h Current market size $7.4bn projected to $11.7bn in 2008 h AstraZeneca will continue to grow its presence through differentiated products h Spectrum of activity h Toxicity profile h I.V. and oral h Monotherapy and combination
Slide 14: ZD0473 - platinum cytotoxic
ZD0473 - platinum cytotoxic Steric hindrance to glutathione N Cl } Different DNA adducts deactivation Pt - altered DNA repair NH3 Cl h Potential advantages – improved toxicity profile – activity in cis/carboplatin resistant tumours – first oral and i.v. platinum cytotoxic In vivo activity of ZD0473
Slide 15: ZD0473 phase I study
ZD0473 - phase I dose escalating study h Main toxicity - myelosuppression – 4 patients with ≥CTC grade 3 myelosuppression at 130 & 150 mg/m2 q3-4 weeks ZD0473 - platinum cytotoxic h Proof of concept monotherapy studies complete h Proof of concept combination studies in progress US and Europe h Respo
Slide 16: ZD9331 - antimetabolite
ZD9331 - antimetabolite h Unique direct TS inhibitor h Exciting broad spectrum preclinical activity with manageable toxicity h Potential for i.v. and oral use h Broad development programme as monotherapy and combination therapy h First submissions from 1H 2002 ZD9331 - activity h Confirmed partial r
Slide 17: Tomudex: Novel approaches
Tomudex Novel approaches h Can broad spectrum, well tolerated oral therapies be developed? – exploiting the new biology
Slide 18: Nolvadex and novel approaches mechanisms
Malignant Cell Proliferation Angiogenesis Neovascular Endothelial Maintainance Metastasis Dissemination Invasion Invasion Malignant Cell Proliferation Angiogenesis Neovascular Endothelial Maintainance ZD1839 FAR ZD6474 CDKI Profile 3 ZD6126 (SRC) (and all marketed products) Nolvadex PAR uPAI PAR SRC
Slide 19: ZD6126
ZD6126 h ZD6126 is a vascular targeting agent h It binds to tubulin h Neovascular cells use the tubulin cytoskeleton to maintain shape h ZD6126 disrupts tubulin, causes neo-endothelial cells to round-up and clot formation h Data in animal models suggest selectivity and relatively wide therapeutic ma
Slide 20: ZD6474
ZD6474 h ZD6474 is a vascular tyrosine kinase inhibitor (VTKI) h Competitive inhibitor of ATP binding site of intracellular tyrosine-kinase component of vascular endothelial growth factor (VEGF) receptor VEGF Endothelial cell membrane Kinase ZD6474 Cell proliferation Nucleus Angiogenesis inhibition
Slide 21: Iressa EGFR tyrosine kinase inhibitor
EGFR tyrosine kinase inhibitor Iressa™ (ZD1839) h EGFR is highly expressed in a EGF-TKI broad range of common solid tumours P TK TK P h Iressa™ is a highly potent and selective inhibitor of the tyrosine kinase P P P ZD 1839 Cl h Inhibits tumour growth in F animal models O NH N O N h Patent to 2016 O
Slide 22: Prostate cancer xenograft
Prostate cancer xenograft Control Iressa™ 1.015 1.784 2.728 4 0.493 0.889 1.347 3.08 0.528 4 0.26 0.117 0.062 0.039 0.031 0.02 3.5 1.394 2.127 3.516 3.5 Start End TUM VOL (cm3) 0.482 0.264 0.106 0.064 0.041 0.034 0.03 TUM VOL (cm3) 3 0.801 2.5 1.217 1.771 2.822 0.624 3 0.37 0.162 0.051 0.031 0.023 0
Slide 23: Iressa development
Iressa™ h Over 170 patients in 4 ongoing trials over 16 months h ~80 patients overall and ~29 patients with NSCLC have received therapeutic doses for >2 months h 5 PRs in NSCLC h ~30 patients with evidence of anti-tumour activity + stable disease associated with symptom improvement h Well tolerated
Slide 24: AstraZeneca Oncology: The major deliverables
AstraZeneca Oncology h A major presence in breast cancer h The world’s leading anti-androgen in prostate cancer h New opportunities in cytotoxics h Leading position in novel approaches h 25,000 patients in trials h 15 products in preclinical and clinical investigation The major deliverables Faslodex
Slide 25: AstraZeneca Oncology
AstraZeneca Oncology h A clear focus to become Number 1 h A clear focus on customer h A clear focus on allowing patients to Live Longer and Better